Cargando…

Virologic Tools for HCV Drug Resistance Testing

Recent advances in molecular biology have led to the development of new antiviral drugs that target specific steps of the Hepatitis C Virus (HCV) lifecycle. These drugs, collectively termed direct-acting antivirals (DAAs), include non-structural (NS) HCV protein inhibitors, NS3/4A protease inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Fourati, Slim, Pawlotsky, Jean-Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690865/
https://www.ncbi.nlm.nih.gov/pubmed/26690198
http://dx.doi.org/10.3390/v7122941
_version_ 1782407050763960320
author Fourati, Slim
Pawlotsky, Jean-Michel
author_facet Fourati, Slim
Pawlotsky, Jean-Michel
author_sort Fourati, Slim
collection PubMed
description Recent advances in molecular biology have led to the development of new antiviral drugs that target specific steps of the Hepatitis C Virus (HCV) lifecycle. These drugs, collectively termed direct-acting antivirals (DAAs), include non-structural (NS) HCV protein inhibitors, NS3/4A protease inhibitors, NS5B RNA-dependent RNA polymerase inhibitors (nucleotide analogues and non-nucleoside inhibitors), and NS5A inhibitors. Due to the high genetic variability of HCV, the outcome of DAA-based therapies may be altered by the selection of amino-acid substitutions located within the targeted proteins, which affect viral susceptibility to the administered compounds. At the drug developmental stage, preclinical and clinical characterization of HCV resistance to new drugs in development is mandatory. In the clinical setting, accurate diagnostic tools have become available to monitor drug resistance in patients who receive treatment with DAAs. In this review, we describe tools available to investigate drug resistance in preclinical studies, clinical trials and clinical practice.
format Online
Article
Text
id pubmed-4690865
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-46908652016-01-04 Virologic Tools for HCV Drug Resistance Testing Fourati, Slim Pawlotsky, Jean-Michel Viruses Review Recent advances in molecular biology have led to the development of new antiviral drugs that target specific steps of the Hepatitis C Virus (HCV) lifecycle. These drugs, collectively termed direct-acting antivirals (DAAs), include non-structural (NS) HCV protein inhibitors, NS3/4A protease inhibitors, NS5B RNA-dependent RNA polymerase inhibitors (nucleotide analogues and non-nucleoside inhibitors), and NS5A inhibitors. Due to the high genetic variability of HCV, the outcome of DAA-based therapies may be altered by the selection of amino-acid substitutions located within the targeted proteins, which affect viral susceptibility to the administered compounds. At the drug developmental stage, preclinical and clinical characterization of HCV resistance to new drugs in development is mandatory. In the clinical setting, accurate diagnostic tools have become available to monitor drug resistance in patients who receive treatment with DAAs. In this review, we describe tools available to investigate drug resistance in preclinical studies, clinical trials and clinical practice. MDPI 2015-12-04 /pmc/articles/PMC4690865/ /pubmed/26690198 http://dx.doi.org/10.3390/v7122941 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Fourati, Slim
Pawlotsky, Jean-Michel
Virologic Tools for HCV Drug Resistance Testing
title Virologic Tools for HCV Drug Resistance Testing
title_full Virologic Tools for HCV Drug Resistance Testing
title_fullStr Virologic Tools for HCV Drug Resistance Testing
title_full_unstemmed Virologic Tools for HCV Drug Resistance Testing
title_short Virologic Tools for HCV Drug Resistance Testing
title_sort virologic tools for hcv drug resistance testing
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690865/
https://www.ncbi.nlm.nih.gov/pubmed/26690198
http://dx.doi.org/10.3390/v7122941
work_keys_str_mv AT fouratislim virologictoolsforhcvdrugresistancetesting
AT pawlotskyjeanmichel virologictoolsforhcvdrugresistancetesting